Session » (1877–1913) Epidemiology & Public Health Poster III

10:30AM-12:30PM

Abstract Number: 1898

Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison

10:30AM-12:30PM

Abstract Number: 1895

Assessing the Validity of Self-Reported Medication Data Through Metabolite Analysis: Data from the Osteoarthritis Initiative

10:30AM-12:30PM

Abstract Number: 1900

Capturing Patient Cohorts: A Temporal Arteritis Classifier

10:30AM-12:30PM

Abstract Number: 1897

Changes in SLE Mortality During and After the COVID-19 Pandemic

10:30AM-12:30PM

Abstract Number: 1911

Characterizing Psoriasis Patients at Risk for Transition to Psoriatic Arthritis: Early Insights from the STOP PsA At-Risk Cohort

10:30AM-12:30PM

Abstract Number: 1908

Clinical and Imaging Features of Haemochromatosis Arthropathy – a Systematic Literature Review and Meta- Analysis

10:30AM-12:30PM

Abstract Number: 1910

Clinical profile and healthcare resource utilization of patients diagnosed with giant cell arteritis or polymyalgia rheumatica in the US: a real-world cohort study using a large database of administrative health claims

10:30AM-12:30PM

Abstract Number: 1878

Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database

10:30AM-12:30PM

Abstract Number: 1912

Cutaneous manifestations of vasculitis: A cross-sectional analysis from an international cohort

10:30AM-12:30PM

Abstract Number: 1877

Demographics and trends of Inflammatory Arthritis-Related Mortality in the United States, 1999–2019

10:30AM-12:30PM

Abstract Number: 1888

Developing Machine Learning Algorithm in Electronic Health Record to Accurately Identify Psoriasis Patients

10:30AM-12:30PM

Abstract Number: 1913

Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration

10:30AM-12:30PM

Abstract Number: 1896

Electronic Cigarette Use in Association with Risks of Developing Rheumatoid Arthritis or Systemic Lupus Erythematosus in the All of Us Research Program

10:30AM-12:30PM

Abstract Number: 1901

Epidemiology of Adult-Onset Still’s Disease in South Korea: A Nationwide Study Using Health Insurance Claims Data

10:30AM-12:30PM

Abstract Number: 1905

Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States

10:30AM-12:30PM

Abstract Number: 1891

Geographic Trends in the Burden of Gout in the United States from 1990 to 2021: A State-Level Analysis of Prevalence, Incidence, and Disability

10:30AM-12:30PM

Abstract Number: 1892

Impact of Systemic Lupus Erythematosus on In-Hospital Outcomes Following Percutaneous Coronary Intervention: Insights from a 7 year Nationwide Analysis

10:30AM-12:30PM

Abstract Number: 1887

Incidence, Prevalence and Mortality of Systemic Lupus Erythematosus – A 20-year territory-wide analysis of electronic health records in Hong Kong

10:30AM-12:30PM

Abstract Number: 1893

Increased Atrial Fibrillation Risk in Rheumatoid Arthritis: Greater in Seropositive Than Seronegative Patients

10:30AM-12:30PM

Abstract Number: 1879

Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study

10:30AM-12:30PM

Abstract Number: 1902

Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases

10:30AM-12:30PM

Abstract Number: 1904

Mapping CTD-ILD in a Spanish Cohort – the NIRRVANA Registry

10:30AM-12:30PM

Abstract Number: 1889

Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe

10:30AM-12:30PM

Abstract Number: 1894

Opioid Use Disorder Among Patients with Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis

10:30AM-12:30PM

Abstract Number: 1890

Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021

10:30AM-12:30PM

Abstract Number: 1899

Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)

10:30AM-12:30PM

Abstract Number: 1880

Rheumatoid Arthritis Mortality in the U.S. (1999–2020): A Decline in Rates, But Not in Disparities

10:30AM-12:30PM

Abstract Number: 1903

Seasonal and Racial/Ethnic Variation in Achieving Target Uric Acid Levels in Gout Patients on Urate Lowering Therapy in US Veterans in Central California

10:30AM-12:30PM

Abstract Number: 1885

Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study

10:30AM-12:30PM

Abstract Number: 1881

Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States

10:30AM-12:30PM

Abstract Number: 1883

Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.

10:30AM-12:30PM

Abstract Number: 1884

The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study

10:30AM-12:30PM

Abstract Number: 1906

The incidence and mortality of connective tissue diseases in England: a population-level cohort study from 2012 to 2023

10:30AM-12:30PM

Abstract Number: 1886

Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication

10:30AM-12:30PM

Abstract Number: 1909

Trends of venous thromboembolism after total joint replacement in the United Kingdom after the introduction of NICE guidelines.

10:30AM-12:30PM

Abstract Number: 1907

Twenty-Year Trends in the U.S. Burden of Gout: A State-Level Analysis of Disability and Prevalence from 2001 to 2021

10:30AM-12:30PM

Abstract Number: 1882

Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020